Safety and efficacy of immune checkpoint inhibitors after allogeneic hematopoietic cell transplantation.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
03
02
2023
accepted:
24
07
2023
revised:
15
07
2023
medline:
9
10
2023
pubmed:
30
7
2023
entrez:
29
7
2023
Statut:
ppublish
Résumé
The immune system plays a major role in preventing infections and cancers. Impairment in immunity may facilitate the development of neoplasia owing to defective immune surveillance, among other mechanisms. Immune evasion plays a significant role in relapse after allogeneic hematopoietic cell transplantation (alloHCT); one purported mechanism is through immune checkpoint signaling pathways. Checkpoint inhibitors (CPIs) are FDA approved for relapsed classical Hodgkin's Lymphoma (cHL), primary mediastinal large B cell Lymphoma (PMBCL) and other solid tumors. Retrospective studies evaluating the outcomes of alloHCT after prior exposure to CPIs showed favorable survival outcomes but high rates of graft-versus-host disease (GVHD); the risk appears to be lower when using post-transplant cyclophosphamide as GVHD prophylaxis. CPIs have increasingly been used to prevent or treat post-alloHCT relapse. Available data, albeit limited, supports the clinical activity of CPIs in post-alloHCT relapse; however, serious and even fatal cases of GVHD have been reported. The optimal timing, schedule, dosing, and patients likely to benefit from this strategy are yet to be identified. In this review, we highlight the immune system's role in cancer surveillance and relapse prevention and discuss the current clinical evidence of CPIs use in post-alloHCT relapse.
Identifiants
pubmed: 37516808
doi: 10.1038/s41409-023-02073-6
pii: 10.1038/s41409-023-02073-6
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1075-1083Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Thomas ED, Lochte HL, Lu WC, Ferrebee JW. Intravenous Infusion of Bone Marrow in Patients Receiving Radiation and Chemotherapy. N. Engl J Med. 1957;257:491–6.
pubmed: 13464965
doi: 10.1056/NEJM195709122571102
Horowitz M, Schreiber H, Elder A, Heidenreich O, Vormoor J, Toffalori C, et al. Epidemiology and biology of relapse after stem cell transplantation. Bone Marrow Transplant. 2018;53:1379–89.
pubmed: 29670211
pmcid: 6282701
doi: 10.1038/s41409-018-0171-z
Blazar BR, Carreno BM, Panoskaltsis-Mortari A, Carter L, Iwai Y, Yagita H, et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol. 2003;171:1272–7.
pubmed: 12874215
doi: 10.4049/jimmunol.171.3.1272
Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21:137–48.
pubmed: 15308095
doi: 10.1016/j.immuni.2004.07.017
Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16–25.
pubmed: 24531241
pmcid: 4388310
doi: 10.1016/j.coi.2014.01.004
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991–8.
pubmed: 12407406
doi: 10.1038/ni1102-991
Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–9.
pubmed: 22193102
pmcid: 3967235
doi: 10.1038/nature10673
Gajewski TF, Fuertes M, Spaapen R, Zheng Y, Kline J. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol. 2011;23:286–92.
pubmed: 21185705
doi: 10.1016/j.coi.2010.11.013
Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14:1014–22.
pubmed: 24048123
pmcid: 4118725
doi: 10.1038/ni.2703
Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14:561–84.
pubmed: 26228759
doi: 10.1038/nrd4591
Kyi C, Postow MA. Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett. 2014;588:368–76.
pubmed: 24161671
doi: 10.1016/j.febslet.2013.10.015
Philips GK, Atkins M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol. 2015;27:39–46.
pubmed: 25323844
doi: 10.1093/intimm/dxu095
Chohan K, Ansell SM. Current salvage therapies in Hodgkin lymphoma. Leuk Lymphoma. 2022;63:1267–80.
pubmed: 35037568
doi: 10.1080/10428194.2021.2024819
Castagna L, Santoro A, Carlo-Stella C. Salvage Therapy for Hodgkin’s Lymphoma: A Review of Current Regimens and Outcomes. J Blood Med. 2020;11:389–403.
pubmed: 33149713
pmcid: 7603406
doi: 10.2147/JBM.S250581
Jacoby MA, Duncavage EJ, Chang GS, Miller CA, Shao J, Elliott K, et al. Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant. JCI Insight. 2018;3:e98962.
pubmed: 29515031
pmcid: 5922277
doi: 10.1172/jci.insight.98962
Quek L, Ferguson P, Metzner M, Ahmed I, Kennedy A, Garnett C, et al. Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia. Blood Adv. 2016;1:193–204.
pubmed: 29296935
pmcid: 5737177
doi: 10.1182/bloodadvances.2016000760
Cairo MS, Jordan CT, Maley CC, Chao C, Melnick A, Armstrong SA, et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biological Considerations of Hematological Relapse following Allogeneic Stem Cell Transplantation Unrelated to Graft-versus-Tumor Effects: State of the Science. Biol Blood Marrow Transplant. 2010;16:709–28.
pubmed: 20227509
pmcid: 3711411
doi: 10.1016/j.bbmt.2010.03.002
Toffalori C, Zito L, Gambacorta V, Riba M, Oliveira G, Bucci G, et al. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat Med. 2019;25:603–11.
pubmed: 30911134
doi: 10.1038/s41591-019-0400-z
Christopher MJ, Petti AA, Rettig MP, Miller CA, Chendamarai E, Duncavage EJ, et al. Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. N Engl J Med. 2018;379:2330–41.
pubmed: 30380364
pmcid: 6322675
doi: 10.1056/NEJMoa1808777
Zeiser R, Vago L. Mechanisms of immune escape after allogeneic hematopoietic cell transplantation. Blood. 2019;133:1290–7.
pubmed: 30578254
doi: 10.1182/blood-2018-10-846824
Norde WJ, Maas F, Hobo W, Korman A, Quigley M, Kester MG, et al. PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation. Cancer Res. 2011;71:5111–22.
pubmed: 21659460
doi: 10.1158/0008-5472.CAN-11-0108
Hutten TJA, Norde WJ, Woestenenk R, Wang RC, Maas F, Kester M, et al. Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8(+) T Cells During Relapse after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transpl. 2018;24:666–77.
doi: 10.1016/j.bbmt.2017.11.027
Manfredi F, Noviello M, Ruggiero E, Perini T, Oliveira G, Cortesi F, et al. Exhausted Central Memory and Memory Stem T Cells Specific for Leukemia Infiltrate the Bone Marrow of AML Patients Relapsing after Allogeneic HSCT. Blood. 2018;132:2028.
doi: 10.1182/blood-2018-99-118104
Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018;36:1428–39.
pubmed: 29584546
pmcid: 6075855
doi: 10.1200/JCO.2017.76.0793
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin’s Lymphoma. N Engl J Med. 2014;372:311–9.
pubmed: 25482239
pmcid: 4348009
doi: 10.1056/NEJMoa1411087
Moskowitz CH, Zinzani PL, Fanale MA, Armand P, Johnson NA, Radford JA, et al. Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study. Blood. 2016;128:1107.
doi: 10.1182/blood.V128.22.1107.1107
Merryman RW, Kim HT, Zinzani PL, Carlo-Stella C, Ansell SM, Perales MA, et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood. 2017;129:1380–8.
pubmed: 28073785
pmcid: 5345733
doi: 10.1182/blood-2016-09-738385
Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D, et al. Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin’s Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26:455–62.
pubmed: 18086796
doi: 10.1200/JCO.2007.13.2415
Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016;127:938–47.
pubmed: 26670632
pmcid: 4760094
doi: 10.1182/blood-2015-09-671834
Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transpl. 2008;14:418–25.
doi: 10.1016/j.bbmt.2008.01.008
Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, et al. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021;35:2672–83.
pubmed: 33658659
doi: 10.1038/s41375-021-01193-6
Perales MA, Awan F, Boumendil A, Chen S, Bazarbachi A, Finel A, et al. Outcomes of allogeneic HCT in patients with Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis. Abstract from the 48th annual EBMT meeting. Bone Marrow Transpl. 2022;57:11–5.
Armand P, Rodig S, Melnichenko V, Thieblemont C, Bouabdallah K, Tumyan G, et al. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. J Clin Oncol. 2019;37:3291–9.
pubmed: 31609651
pmcid: 6881098
doi: 10.1200/JCO.19.01389
Zinzani PL, Santoro A, Gritti G, Brice P, Barr PM, Kuruvilla J, et al. Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study. J Clin Oncol. 2019;37:3081–9.
pubmed: 31398081
pmcid: 6864847
doi: 10.1200/JCO.19.01492
Oran B, Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, et al. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer. 2020;126:2193–205.
pubmed: 32125707
doi: 10.1002/cncr.32796
Tschernia NP, Kumar V, Moore DT, Vincent BG, Coombs CC, Van Deventer H, et al. Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia. Transpl Cell Ther. 2021;27:1021.e1–5.
doi: 10.1016/j.jtct.2021.08.022
Nieto JC, Roldán E, Jiménez I, Fox L, Carabia J, Ortí G, et al. Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy. Leukemia. 2020;34:3420–5.
pubmed: 32393842
doi: 10.1038/s41375-020-0851-8
Herbaux C, Merryman R, Devine S, Armand P, Houot R, Morschhauser F, et al. Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. Blood. 2018;132:9–16.
pubmed: 29720488
doi: 10.1182/blood-2018-02-811174
Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Sharpe AH, Vallera DA. Opposing Roles of CD28:B7 and CTLA-4:B7 Pathways in Regulating In Vivo Alloresponses in Murine Recipients of MHC Disparate T Cells. J Immunol. 1999;162:6368–77.
pubmed: 10352249
doi: 10.4049/jimmunol.162.11.6368
Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009;113:1581–8.
pubmed: 18974373
pmcid: 2644086
doi: 10.1182/blood-2008-07-168468
Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, et al. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016;375:143–53.
pubmed: 27410923
pmcid: 5149459
doi: 10.1056/NEJMoa1601202
Khouri IF, Fernandez Curbelo I, Turturro F, Jabbour EJ, Milton DR, Bassett RL Jr, et al. Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. Clin Cancer Res. 2018;24:1011–8.
pubmed: 29246938
doi: 10.1158/1078-0432.CCR-17-2777
Angenendt L, Schliemann C, Lutz M, Rebber E, Schulze AB, Weckesser M, et al. Nivolumab in a patient with refractory Hodgkin’s lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51:443–5.
pubmed: 26551782
doi: 10.1038/bmt.2015.266
Yared JA, Hardy N, Singh Z, Hajj S, Badros AZ, Kocoglu M, et al. Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51:850–2.
pubmed: 26828905
doi: 10.1038/bmt.2015.346
Aslan A, Aras T, Özdemir E. Successful treatment of relapsed/refractory Hodgkins lymphoma with nivolumab in a heavily pretreated patient with progressive disease after both autologous and allogeneic stem cell transplantation. Leuk Lymphoma. 2017;58:754–5.
pubmed: 27687237
doi: 10.1080/10428194.2016.1213835
Mori S, Ahmed W, Patel RD, Dohrer AL. Steroid Refractory Acute Liver GVHD in a Hodgkin’s Patient after Allogeneic Stem Transplant Cell Transplantation Following Treatment with Anti PD-1 Antibody, Nivolumab, for Relapsed Disease. Biol Blood Marrow Transplant. 2016;22:S392–S3.
doi: 10.1016/j.bbmt.2015.11.916
Singh AK, Porrata LF, Aljitawi O, Lin T, Shune L, Ganguly S, et al. Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin’s lymphoma. Bone Marrow Transplant. 2016;51:1268–70.
pubmed: 27111048
doi: 10.1038/bmt.2016.111
De la Hoz A, Foolad F, Gallegos C, Kornblau S, Kontoyiannis DP. Nivolumab–induced encephalitis post allogeneic stem cell transplant in a patient with Hodgkin’s disease. Bone Marrow Transplant. 2019;54:749–51.
pubmed: 30323308
doi: 10.1038/s41409-018-0363-6
Herbaux C, Gauthier J, Brice P, Drumez E, Ysebaert L, Doyen H, et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood. 2017;129:2471–8.
pubmed: 28270452
doi: 10.1182/blood-2016-11-749556
Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, et al. PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017;130:221–8.
pubmed: 28468799
pmcid: 5510790
doi: 10.1182/blood-2017-01-761346
Herrera AF, Burton C, Radford J, Miall F, Townsend W, Santoro A, et al. Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial. Blood Adv. 2021;5:3387–96.
pubmed: 34477818
pmcid: 8525219
doi: 10.1182/bloodadvances.2021004511
Holderried TAW, Fraccaroli A, Schumacher M, Heine A, Brossart P, Stelljes M, et al. The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin’s Lymphoma. Bone Marrow Transpl. 2019;54:1662–7.
doi: 10.1038/s41409-019-0498-0
Tang Y, Zhou Z, Yan H, You Y. Case Report: Preemptive Treatment With Low-Dose PD-1 Blockade and Azacitidine for Molecular Relapsed Acute Myeloid Leukemia With RUNX1-RUNX1T1 After Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol. 2022;13:810284.
pubmed: 35185899
pmcid: 8847388
doi: 10.3389/fimmu.2022.810284
Davids MS, Kim HT, Costello C, Herrera AF, Locke FL, Maegawa RO, et al. A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood. 2020;135:2182–91.
pubmed: 32478814
pmcid: 7290092
doi: 10.1182/blood.2019004710
Wang AY, Kline J, Stock W, Kosuri S, Artz A, Larson RA, et al. Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transpl. 2020;26:1025–7.
doi: 10.1016/j.bbmt.2020.01.021
Schmid C, Labopin M, Nagler A, Bornhäuser M, Finke J, Fassas A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol. 2007;25:4938–45.
pubmed: 17909197
doi: 10.1200/JCO.2007.11.6053
Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R, et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood. 2012;119:1599–606.
pubmed: 22167752
doi: 10.1182/blood-2011-08-375840
Shiobara S, Nakao S, Ueda M, Yamazaki H, Takahashi S, Asano S, et al. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome. Bone Marrow Transplant. 2000;26:769–74.
pubmed: 11042659
doi: 10.1038/sj.bmt.1702596
Takami A, Yano S, Yokoyama H, Kuwatsuka Y, Yamaguchi T, Kanda Y, et al. Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transpl. 2014;20:1785–90.
doi: 10.1016/j.bbmt.2014.07.010
Bejanyan N, Weisdorf DJ, Logan BR, Wang HL, Devine SM, de Lima M, et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Transpl. 2015;21:454–9.
doi: 10.1016/j.bbmt.2014.11.007
Chen Y-H, Zhang X, Cheng Y-F, Chen H, Mo X-D, Yan C-H, et al. Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Cytotherapy. 2020;22:755–61.
pubmed: 32861622
doi: 10.1016/j.jcyt.2020.08.002
Zhang C, Wang X-Q, Zhang R-L, Liu F, Wang Y, Yan Z-L, et al. Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant. Leukemia. 2021;35:1563–70.
pubmed: 33077866
doi: 10.1038/s41375-020-01056-6
Liu S, Deng B, Yin Z, Lin Y, An L, Liu D, et al. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. Am J Hematol. 2021;96:671–9.
pubmed: 33725422
doi: 10.1002/ajh.26160
Hua J, Zhang J, Wu X, Zhou L, Bao X, Han Y, et al. Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2020;20:610–6.
pubmed: 32507386
doi: 10.1016/j.clml.2020.04.007
Brudno JN, Somerville RPT, Shi V, Rose JJ, Halverson DC, Fowler DH, et al. Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. J Clin Oncol. 2016;34:1112–21.
pubmed: 26811520
pmcid: 4872017
doi: 10.1200/JCO.2015.64.5929
Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, et al. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Investig. 2016;126:3363–76.
pubmed: 27482888
pmcid: 5004935
doi: 10.1172/JCI86721
Dai H, Zhang W, Li X, Han Q, Guo Y, Zhang Y, et al. Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncoimmunology. 2015;4:e1027469.
pubmed: 26451310
pmcid: 4590028
doi: 10.1080/2162402X.2015.1027469
Ding L, Wang Y, Hong R, Zhao H, Zhou L, Wei G, et al. Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse. Front Oncol. 2021;11:750218.
pubmed: 34790576
pmcid: 8591161
doi: 10.3389/fonc.2021.750218
Liu P, Liu M, Lyu C, Lu W, Cui R, Wang J, et al. Acute Graft-Versus-Host Disease After Humanized Anti-CD19-CAR T Therapy in Relapsed B-ALL Patients After Allogeneic Hematopoietic Stem Cell Transplant. Front Oncol. 2020;10:573822.
pubmed: 33117709
pmcid: 7551306
doi: 10.3389/fonc.2020.573822
Jain T, Sauter CS, Shah GL, Maloy MA, Chan J, Scordo M, et al. Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma. Leukemia. 2019;33:2540–4.
pubmed: 31114023
pmcid: 8224498
doi: 10.1038/s41375-019-0476-y
Lutfi F, Holtzman N, Siglin J, Bukhari A, Mustafa Ali M, Kim D, et al. Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed/refractory large B-cell lymphoma. Br J Haematol. 2021;192:212–6.
pubmed: 33169845
doi: 10.1111/bjh.17121
Schubert M-L, Dietrich S, Stilgenbauer S, Schmitt A, Pavel P, Kunz A, et al. Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020;26:1575–80.
pubmed: 32422254
doi: 10.1016/j.bbmt.2020.04.025
Chen X, Li X, Liu Y, Zhang Z, Zhang X, Huang J, et al. A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma. Immunotherapy. 2020;12:681–96.
pubmed: 32580597
doi: 10.2217/imt-2020-0022
Alkhaldi H, Sewell D, Ning Y, Kallen ME, Emadi A, Hardy NM, et al. Durable response to ivosidenib in post-transplant relapse and leukemic transformation of myelodysplastic syndrome with new complex karyotype and IDH1 R132C mutation. Leuk Lymphoma. 2022;63:3000–3.
pubmed: 35938721
doi: 10.1080/10428194.2022.2105329
DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, et al. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med. 2018;378:2386–98.
pubmed: 29860938
doi: 10.1056/NEJMoa1716984
Stein EM. Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia. Fut Oncol. 2018;14:23–40.
doi: 10.2217/fon-2017-0392